久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

Pharmaceutical companies seek global solutions

Updated: 2012-10-09 08:02

By Liu Jie (China Daily)

  Print Mail Large Medium  Small 分享按鈕 0

Pharmaceutical companies seek global solutions

A Shanghai Fosun Pharmaceutical (Group) Co Ltd display at a medical exhibition. The company has decided to expand in foreign markets by setting up plants overseas. Jing Wei / for China Daily

Pharmaceutical companies seek global solutions

Thierry Bernard doesn't need to be convinced of the quality of China's healthcare industry.

But the vice-president of commercial operations, worldwide sales, marketing and customer service at the French company bioMerieux, says there is still widespread bias against Chinese firms, among some in the industry.

After 20 years in China, Bernard's firm, a worldwide group specializing in vitro diagnostics for medical and industrial applications, set up a joint venture with Shanghai Kehua Bio-engineering Co Ltd, a major Chinese diagnostic company, in 2007.

It also acquired the fast-detection equipment producer Meikang Biotechnology (Shanghai) Co Ltd in 2010.

The French firm, which boasts a network covering more than 150 nations and regions, has since been helping its Chinese partners sell their products and promote their technologies around the world.

As far as Bernard is concerned, such joint venture agreements with Chinese companies are mutually beneficial, in their efforts to expand their international market.

China has now become bioMerieux's third-largest market by sales, only after France and the United States. Its annual growth now increasing between 20 percent and 25 percent, compared with the company's global growth of 5 percent to 6 percent.

"The Chinese companies don't need our money. They have plenty of cash. But we certainly need their experience in the local market, and their knowledge of emerging markets", he says.

"But there is still a bias against Chinese companies by some US and European counterparts, which still doubt the merits of forming mergers with, or making acquisitions of, companies here."

Bernard adds that China's leading healthcare companies compete well in three areas, in what is a highly competitive worldwide industry: on price, on creativity and on their ability to produce products that are easy to make and highly efficient.

Despite the international bias suggested by Bernard, the list of Chinese companies looking to increase their international presence is becoming longer, whether they want to set up manufacturing plants overseas, list on foreign stock exchanges, or establish joint ventures with multinational partners.

One such company is BGI (Beijing Genomics Institute)Shenzhen.

On Sept 17, it announced plans to acquire Complete Genomics Inc, a US-based leader in whole human genomic sequencing, for $117.6 million.

Whole human genome sequencing is used by research centers to conduct medical research that in the future is expected to be used by doctors and hospitals to improve both prevention and treatment of various types of disease.

BGI-Shenzhen operates international genome sequencing centers, which support genetic research into agriculture, animals and humans.

It is hoped that the combination of the two companies will result in an operation that brings together complementary scientific and technological expertise and research and development capabilities.

One local press report in the US suggested recently, "the acquisition could be read as a signal to the world that China is determined to be a major competitor in the future genome sequencing market".

Ben Sim, a spokesperson for BGI-Shenzhen, says Complete will concentrate on medical research in an ambitious effort to speed up clinical trials and advance the era of personalized medicine, while BGI-Shenzhen's businesses are broader, and the government has approved it to do clinical research domestically.

The deal appears to be a perfect example of international cooperation that benefits both sides, according to Bruce Liu, a partner, and head of the medical care unit, at Roland Berger Strategy Consultants.

He says overseas M&As by Chinese companies are ideally aimed at expansion of product portfolios, the marrying of complementary technologies, and the best use of foreign resources, such as knowledge and distribution networks in local markets.

But he says that some Chinese companies have chosen other avenues for international expansion.

The Shanghai biopharmaceutical enterprise Fosun Pharmaceutical Group Co Ltd, for example, has chosen to take the more conventional route of organic expansion in a foreign market, he says.

In July, it set up a plant in Cote d'Ivoire, aiming to cover 17 nations and regions across the western side of the African continent.

In late August, it received a five-year, 300-million-yuan ($47.2 million) loan from International Financing Corp for its overseas ambitions.

Liu explains that Fosun's main product in Africa is Artemisinin, a new anti-malarial drug, extracted from a traditional herb grown locally.

"Establishing a production base in Africa means getting close to the raw materials it needs to produce the drugs, and the patients it needs to treat," he said.

However, different from the Fosun example, many Chinese companies believe cooperation with foreign counterparts is the safer and easier way to explore an international market.

Bernard says his company hopes to build more partnerships with local Chinese healthcare counterparts, to help it enter other foreign markets, aided by the French company's existing global sales network.

"It is very expensive to create new channels. But Chinese companies can take advantage of the network we have spent 40 years to set up," he says.

Amir Yaar, one of the leading financial entrepreneurs in Israel, also wants to help Chinese medical companies go abroad.

Last year Israeli set up China Israel Synergy Group, an international investment and cooperation advisory company whose aim is to promote investments between China and Israeli technology and innovation companies.

Working both in China and Israel, Yaar says: "I want to create a means for Chinese medical enterprises and Israeli high-tech companies to explore international markets."

He says his research shows that Chinese companies have huge advantages in their manufacturing capability, high-quality workforce, and wide clinical research base, while Israeli companies, especially some small and medium-sized ones, enjoy cutting edge research and development ability, and financial strength.

"By bringing Israeli technology, to be produced in China by local companies, we can help promote products, including pharmaceuticals and medical devices, to the international market.

"The combination will provide technological expertise at competitive prices," he said, adding that any profit will be used to fund further R&D by Israeli companies, and expand manufacturing activities within China.

"We are now undergoing administrative procedures in China and can officially open we hope, within months."

Another recent high-profile contract signing between Chinese and international partners involved Life Technologies Corp, the US-based global biotechnology leader, and Sino Biological Inc, the leading Chinese biotech company.

The two have agreed to a partnership for worldwide product distribution and development.

Life Technologies will distribute Sino's large portfolio of recombinant proteins, antibodies and other products using its global distribution channels in more than 160 nations and regions.

The two companies will also jointly develop new products, using various research and development assets to introduce innovative products more quickly.

In a statement, the firms said that by working with one another, the companies are well positioned to provide proteomics products to a global customer base, and as two of the leading life science brands in China, contribute to accelerating the expansion of the Chinese biotech industry.

The agreement is believed to be the first by a US-based company, aimed at helping its Chinese counterpart not only to sell products, but also build its brands globally.

Proteins and antibodies are the fundamental means employed by pharmaceutical researchers and academic scientists to aid the discovery of new therapeutic targets in the process of new drug development.

According to Gregory T. Lucier, chairman and CEO of Life Technologies, all the products involved - more than 6,000 human-derived proteins and antibodies - are to be sold under the brands of Sino Biological and Life Technologies.

"We will first sell Sino Biological's products in the United States, then expand to Europe and South America," said Lucier.

Bruce Liu said Chinese pharmaceutical companies have become well-known as excelling in treatments for cancer, cardiovascular disease and neurological illnesses, as well as the development of new drug delivery models, biopharmaceutical generics and biological engineering.

"Large companies engaged in these sectors already have strength to go abroad, especially to big developing markets, such as Brazil and Latin American nations," says Liu.

He adds that Fosun's entry into Africa, in particular, was helped by its being included on the United Nations' list of qualified manufacturers of malaria medicine for underdeveloped African nations and regions.

Meng Dongping, vice-president of the China Chamber of Commerce for Import & Export of Medicines & Health Products, adds: "Although, we have no specific statistics of how many Chinese drugmakers and medical device producers have managed successful overseas expansions, from our observations, the number has increased very fast in recent years.

"A large number have gone into developing markets, such as Southeast Asia and East Europe, but more and more are eyeing the mature Western market."

But Liu warns Chinese companies have to be "smart" when choosing a destination.

"Entry into underdeveloped and developing markets is faster and easier, but companies will face serious competition in terms of price and quantity," he said.

"Developed markets can also be more difficult and time-consuming, because of the high threshold set on technical standards, and long registration, approval and certification procedures.

"But if successful, they can prove a breakthrough for companies - a guarantee of fat profits and stable growth over a certain period of time.

"But they must make sure they carefully research local governmental regulations, industrial practices, consuming preferences and even labor quality."

Meng advises Chinese firms to go one step further and always consider employing professional consultancies, or getting advice from government departments, industrial associations and third-party consulting firms that might have a presence in any potential new market.

But above all, says Bernard of bioMerieux, when looking abroad, Chinese companies must check and make sure of the credentials of any potential partner.

"What they should always keep in mind is insisting on quality, quality and quality."

liujie@chinadaily.com.cn

(China Daily 10/09/2012 page13)

久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    免费观看在线综合色| 成人免费看片app下载| 精品奇米国产一区二区三区| 久久疯狂做爰流白浆xx| 久久久久久电影| 99久久精品费精品国产一区二区| 一区二区三区在线观看网站| 欧美三级视频在线观看| 免费观看日韩av| 久久久www成人免费无遮挡大片| 成人av午夜电影| 一二三区精品视频| 欧美一区二区日韩| 国产美女精品一区二区三区| 国产精品二三区| 欧美三级乱人伦电影| 毛片av一区二区三区| 国产日韩欧美不卡| 欧美自拍偷拍午夜视频| 蜜臀久久99精品久久久久久9| 国产视频911| 欧美这里有精品| 久久99热这里只有精品| 国产精品女人毛片| 欧美日韩一卡二卡| 国产一区二区精品在线观看| 亚洲婷婷综合久久一本伊一区| 欧美精选一区二区| 国产精品888| 亚洲影视在线观看| 精品国产乱码久久久久久蜜臀| yourporn久久国产精品| 调教+趴+乳夹+国产+精品| 久久久国产一区二区三区四区小说| 色久优优欧美色久优优| 久久国产日韩欧美精品| 亚洲人成伊人成综合网小说| 日韩午夜三级在线| 91免费小视频| 捆绑调教美女网站视频一区| 亚洲黄色av一区| 久久蜜桃香蕉精品一区二区三区| 在线亚洲一区二区| 国产美女主播视频一区| 亚洲国产成人va在线观看天堂| 久久婷婷国产综合国色天香| 欧美视频日韩视频| 成人性色生活片免费看爆迷你毛片| 亚洲成人自拍网| 亚洲国产精品国自产拍av| 在线成人小视频| 99国产精品视频免费观看| 美日韩一区二区| 一区二区三区四区五区视频在线观看| 欧美mv日韩mv亚洲| 欧美午夜一区二区三区| 国产91精品久久久久久久网曝门| 五月天激情小说综合| 国产精品久久久久久久久免费丝袜 | 午夜日韩在线电影| 国产精品免费丝袜| 日韩精品一区在线观看| 欧美日韩一卡二卡三卡 | 午夜私人影院久久久久| 中文字幕一区在线观看视频| 精品国产乱子伦一区| 欧美高清激情brazzers| 91麻豆免费观看| 粉嫩av一区二区三区| 麻豆专区一区二区三区四区五区| 亚洲高清视频中文字幕| 日韩理论电影院| 中文文精品字幕一区二区| 精品国产sm最大网站| 在线成人午夜影院| 欧美日韩综合在线| 91在线观看污| 国产a精品视频| 国产一区二区视频在线| 日本午夜精品一区二区三区电影| 亚洲午夜视频在线观看| 伊人婷婷欧美激情| 中文字幕一区二区在线播放 | 久久五月婷婷丁香社区| 日韩欧美123| 这里只有精品视频在线观看| 精品久久久久av影院| 欧美一区二区成人6969| 3d动漫精品啪啪1区2区免费| 欧美视频自拍偷拍| 欧美午夜在线一二页| 欧洲视频一区二区| 91国产精品成人| 色婷婷久久久综合中文字幕| 91香蕉视频mp4| 91丨九色porny丨蝌蚪| 成人免费毛片a| 成人av午夜影院| aaa欧美大片| 91在线国产福利| 91视频国产观看| 色综合天天性综合| 91香蕉国产在线观看软件| 91在线云播放| 色综合天天综合狠狠| 在线观看日韩毛片| 欧美亚一区二区| 欧美日韩国产中文| 欧美日韩高清一区二区三区| 欧美精品三级日韩久久| 69久久夜色精品国产69蝌蚪网| 欧美一区二区日韩一区二区| 日韩欧美不卡在线观看视频| www成人在线观看| 欧美激情一区在线观看| 国产精品久久久久一区二区三区 | 国产高清亚洲一区| 国产·精品毛片| 北条麻妃国产九九精品视频| 91美女片黄在线观看| 在线观看日产精品| 欧美精品久久99| 日韩欧美一级精品久久| 久久综合九色欧美综合狠狠| 中文字幕成人网| 亚洲精品视频自拍| 午夜精品福利视频网站| 免费在线看成人av| 国产一区二区导航在线播放| 成人免费av资源| 在线一区二区三区四区五区| 7777精品久久久大香线蕉| 亚洲精品一区二区三区在线观看| 亚洲国产精品国自产拍av| 亚洲视频每日更新| 性做久久久久久久免费看| 亚洲高清在线精品| 韩国女主播成人在线| 成人亚洲精品久久久久软件| 91免费版在线看| 99v久久综合狠狠综合久久| 欧美在线不卡一区| 91精品国产综合久久久久久漫画| 日韩一区二区免费在线电影| 国产欧美一区二区精品仙草咪| 中文成人av在线| 亚洲免费在线观看| 亚洲成人免费视频| 国内一区二区视频| va亚洲va日韩不卡在线观看| 在线观看亚洲精品| 国产日韩欧美精品一区| 中文字幕一区日韩精品欧美| 一区二区不卡在线视频 午夜欧美不卡在 | 精品日产卡一卡二卡麻豆| 亚洲欧洲美洲综合色网| 夜夜嗨av一区二区三区四季av| 性欧美大战久久久久久久久| 久久精品国产精品青草| 国产乱码一区二区三区| 99精品视频在线播放观看| 欧美日韩一本到| 欧美精品一区二区不卡| 一区二区久久久久久| 美女网站色91| 99久久亚洲一区二区三区青草| 欧美日韩一二三区| 国产精品嫩草99a| 日韩在线a电影| 国产成人自拍在线| 色综合久久综合网欧美综合网| 51精品视频一区二区三区| 日韩高清在线不卡| 国产成人av电影免费在线观看| 欧美日韩一区二区三区高清 | 中文字幕第一区| 一二三四区精品视频| 国产一区二区精品久久91| 欧洲国产伦久久久久久久| 精品国精品国产尤物美女| 亚洲丝袜制服诱惑| 国产原创一区二区| 欧美性猛片aaaaaaa做受| 久久嫩草精品久久久久| 午夜视频一区二区三区| 懂色中文一区二区在线播放| 在线播放一区二区三区| 国产精品网曝门| 日本在线不卡视频| 99re6这里只有精品视频在线观看| 日韩欧美专区在线| 一区二区三区加勒比av| 成人小视频免费观看| 日韩欧美亚洲国产另类| 亚洲黄色尤物视频| 国产成人精品免费视频网站| 精品国产亚洲一区二区三区在线观看| 一区二区三区中文在线观看| 国产精品 欧美精品| 欧美日韩一区二区三区不卡|